Abstract: Disclosed are inhibitors for the ?-catenin/BCL9 interaction. The inhibitors are selective for ?-catenin/BCL9 over ?-catenin/cadhenin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: Disclosed are inhibitors for the ?-catenin/BCL9 interaction. The inhibitors are selective for ?-catenin/BCL9 over ?-catenin/cadherin in-teractions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: The present disclosure relates to real-time localization error correction of an autonomous vehicle (AV). A processor for real-time localization error correction of the AV is provided. The processor is configured to retrieve a reference landmark around the AV from a map aggregating server (MAS), wherein the AV is configured to interact with the MAS for real-time localization; detect, in real time, a ground truth landmark corresponding to the reference landmark, according to image data captured by one or more image capture devices installed on the AV; and determine a deviation between the ground truth landmark and the reference landmark as a real-time correction value for the real-time localization of the AV.

Abstract: In one aspect, the invention relates to 4-substituted benzoylpiperazine-1-substituted carbonyls, derivatives thereof, and related compounds; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g., various tumors and cancers, associated with ?-catenin/BCL9 protein-protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: In one aspect, the invention relates to 4-substituted benzoylpiperazine-1-substituted carbonyls having a structure represented by a formula: derivatives thereof, and related compounds; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g., various tumors and cancers, associated with ?-catenin/BCL9 protein-protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Disclosed are inhibitors for the ?-catenin/BCL9 interaction. The inhibitors are selective for ?-catenin/BCL9 over ?-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: Disclosed are inhibitors for the ?-catenin/BCL9 interaction. The inhibitors are selective for ?-catenin/BCL9 over D catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: Disclosed are inhibitors for the ?-catenin/B-cell lymphoma 9 interaction. The inhibitors are selective for ?-catenin/B-cell lymphoma 9 over ?-catenin/E-cadherin PPI interaction. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: Disclosed are inhibitors for the ?-catenin/T-cell factor interaction. The inhibitors are selective for ?-catenin/T-cell factor over ?-catenin/cadherin and ?-catenin/APC interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: One or more processors may be configured to determine one or more prospective routes of an ego vehicle being at least partially controlled by a human driver; receive first sensor data, representing one or more attributes of a second vehicle; determine a danger probability of the one or more prospective routes of the first vehicle using the at least the one or more attributes of the second vehicle from the first sensor data; and if each of the one or more prospective routes of the first vehicle has a danger probability outside of a predetermined range, send a signal representing a safety intervention. Whenever a safety intervention signal is sent, the one or more processors may be configured to increment or decrement a counter.

Abstract: Embodiments of the present disclosure provide devices, techniques, and configurations for network interface controllers (NICs) that log write packets received from a network in non-volatile random access memory (NVRAM). In one embodiment, a NIC includes a network interface to couple a host of the NIC to a network, a NVRAM, and a controller coupled with the network interface and the NVRAM, where the controller is to log write packets received at the network interface from the network in the NVRAM. Other embodiments may be described and/or claimed.

Abstract: Disclosed are compositions and methods for engineered peptide inhibitors of NLRP3 infiammasome and methods of their use in the treatment of Myelodysplastic Syndromes. In one aspect, disclosed herein are engineered inhibitors of NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome comprising a Helix 2 of POP1 comprising one or more substitutions at residues 18, 21, 22, 25, 26, 28, 29, and/or 30 of POP1 as set forth in SEQ ID NO:1.

Abstract: A safety system (200) for a vehicle (100) is provided. The safety system (200) may include one or more processors (102). The one or more processors (102) may be configured to control a vehicle (100) to operate in accordance with the predefined stored driving model parameters, to detect vehicle operation data during the operation of the vehicle (100), to determine whether to change predefined driving model parameters based on the detected vehicle operation data and the driving model parameters, to change the driving model parameters to changed driving model parameters, and to control the vehicle (100) to operate in accordance with the changed driving model parameters.

Abstract: Disclosed herein is a series of helical sulfono-?-AApeptides that mimic the binding mode of the ?-helical HD2 domain of B-Cell Lymphoma 9 (BCL9). As disclosed herein, sulfono-?-AApeptides can structurally and functionally mimic the ?-helical domain of BCL9, and selectively disrupt ?-catenin/BCL9 PPIs with even higher potency. More intriguingly, these sulfono-?-AApeptides can enter cancer cells, bind with ?-catenin and disrupt ?-catenin/BCL PPI, and exhibit excellent cellular activity, which is much more potent than the BCL9 peptide. Furthermore, enzymatic stability studies demonstrated the remarkable stability of the helical sulfono-?-AApeptides, with no degradation in the presence of pronase for 24 h, augmenting their biological potential.

Abstract: Disclosed herein are small molecule pyrin-domain targeted NLRP3 inflammasome inhibitors.

Abstract: Disclosed are inhibitors for the ?-catenin/T-cell factor interaction. The inhibitors are selective for ?-catenin/T-cell factor over ?-catenin/phosphocadherin, and ?-catenin/phosphoAPC interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: Disclosed are inhibitors for the ?-catenin/BCL9 interaction. The inhibitors are selective for ?-catenin/BCL9 over ?-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: Disclosed are inhibitors for the ?-catenin/BCL9 interaction. The inhibitors are selective for ?-catenin/BCL9 over ?-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: The present disclosure relates to real-time localization error correction of an autonomous vehicle (AV). A processor for real-time localization error correction of the AV is provided. The processor is configured to retrieve a reference landmark around the AV from a map aggregating server (MAS), wherein the AV is configured to interact with the MAS for real-time localization; detect, in real time, a ground truth landmark corresponding to the reference landmark, according to image data captured by one or more image capture devices installed on the AV; and determine a deviation between the ground truth landmark and the reference landmark as a real-time correction value for the real-time localization of the AV.

Abstract: An embodiment of a memory apparatus may include a logger to log memory access data in persistent storage media, a log indexer communicatively coupled to the logger to index the memory access log data in an index table in a system memory, and a key compressor communicatively coupled to the log indexer to compress an index key for the index table. Other embodiments are disclosed and claimed.